Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score
Psychiatric Times
JUNE 13, 2025
VMAT2 inhibitors, approved in 2017, represent a significant advancement in the treatment of TD, offering evidence-based options for managing symptoms. Miller, MD Key Takeaways TD is often underreported and misdiagnosed, despite being a well-known adverse effect of antipsychotic medications, leading to inadequate treatment.
Let's personalize your content